1. HYPERTENSION (HTN) IN PATIENTS (PTS) TREATED WITH IBRUTINIB (IBR) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (12th June 2019) Authors: Sarraf Yazdy, M.; Roeker, L.; Gashonia, L.; Goodfriend, J.; Narkhede, M.; Rhodes, J.; Kennard, K.; Morse, H.; Dorsey, C.; Battiato, K.; Deonarine, I.; Carver, J.; Schuster, S.J.; Cheson, B.D.; Mato, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Measuring quantitative proteomic distance between Spanish beef breeds. (15th June 2020) Authors: Rodríguez-Vázquez, R.; Mato, A.; López-Pedrouso, M.; Franco, D.; Sentandreu, M.A.; Zapata, C. Journal: Food chemistry Issue: Volume 315(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P626: FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL. (23rd June 2022) Authors: Skånland, S.; Yanping, Y.; Athanasiadis, P.; Karlsen, L.; Urban, A.; Murali, I.; Fernandes, S.; Hilli, A.; Taskén, K.; Bertoni, F.; Mato, A.; Normant, E.; Brown, J.; Tjønnfjord, G.; Aittokallio, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES. (23rd June 2022) Authors: Mato, A.; Danilov, A.; Patel, M. R.; Tees, M.; Flinn, I.; Ai, W.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; Tan, M.; Meredith, E.; Gessner, M.; Kim, S. Y.; Wiestner, A.; Wierda, W. G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE. (23rd June 2022) Authors: Eyre, T. A.; Hess, L.; Sugihara, T.; Walgren, R. A.; Abada, P. B.; Konig, H.; Pagel, J.; Roeker, L. E.; Mato, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P675: TREATMENT OF HYPERTENSION IN PATIENTS RECEIVING BTK INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY. (23rd June 2022) Authors: Shadman, M.; Voutsinas, J.; Fakhri, B.; Khajavian, S.; Spurgeon, S.; Stephens, D.; Skarnbik, A.; Mato, A.; Broome, C.; Gopal, A.; Smith, S.; Lynch, R.; Rainey, M.; Kim, S.; Barrett-Campbell, O.; Hemond, E.; Tsang, M.; Ermann, D.; Malakhov, N.; Rao, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. (June 2017) Authors: Sharman, J.P.; Brander, D.M.; Mato, A.; Kambhampati, S.; Burke, J.M.; Lansigan, F.; Schreeder, M.T.; Lunin, S.D.; Ghosh, N.; Zweibach, A.; Shtivelband, M.I.; Travis, P.M.; Chandler, J.; Kolibaba, K.S.; Sporteli, P.; Miskin, H.P.; Weiss, M.S.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗